Escherichia coli (
E. coli) and
Klebsiella pneumoniae (
K. pneumoniae) are opportunistic Gram-negative
bacilli of the
Enterobacteriaceae family and cause nosocomial infections.
K. pneumoniae causes pneumonia, sepsis, and urinary tract infections, and
E. coli is an indicator of urinary tract infection and causes pneumonia, sepsis, and bacteremia (
1,
2).
Bacteria are immune to the harmful effects of antibiotics using a variety of mechanisms, one of which is the production of broad-spectrum beta-lactamases (ESBL) enzymes (
3). Today, the prevalence of broad-spectrum beta-lactamase-producing bacteria is increasing and has raised concerns in treatment systems because they increase treatment costs, increase treatment duration, and increase mortality in patients (
4). According to the results of studies, Gram-negative bacteria of
E. coli and
K. pneumoniae have the highest resistance, and mainly these strains carry ESBLs (
5,
6). ESBLs are divided into 4 classes (A, B, C, D), which are mainly inhibited by inhibitors such as clavulanic acid, tazobactam, and sulbactam (
7). According to this classification, the enzymes SHV, TEM, and CTX-M are in class A (
8). More than 150 ESBLs have been reported so far. Broad-spectrum beta-lactamases are broad-spectrum hydrolyzing enzymes of cephalosporins (
9). ESBLs are located on the plasmid, so they are easily transferable between different strains. The most common ESBLs are derived from TEM and SHV (
10). Beta-lactamase TEM-1 is the most common beta-lactamase in Gram-negative bacilli Enterobacteriaceae family. Different types of beta-lactamase TEM have been formed by substituting amino acids for the active site of the TEM-1 enzyme, based on which about 130 beta-lactamase TEM has been identified. SHV beta-lactamase was first discovered by Pitton in 1972, which is a class A beta-lactamase. In the last two decades, widespread prevalence of CTX-M beta-lactamases has been reported in various regions (
11-
13). The first reports of CTX-M were recorded in the early 1990s. Unlike TEM and SHV, CTX-M beta-lactamases have a more destructive effect against cefotaxime and ceftriaxone than ceftazidime. CTX-M beta-lactamases are divided into five main groups based on amino acid changes, including CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 (
10).
Therefore, considering the transfer of resistance genes by ESBL isolates and the identification of ESBL-producing isolates, it is very important to isolate these isolates to prevent treatment failure (
14,
15). A simple and inexpensive phenotypic technique for isolating these isolates is the double-disc synergy test (DDST), which can be performed in many laboratories (
14).